ATLAS / Macro Radar / Reporting / ERAS

Erasca, Inc. (ERAS) reporting calendar

Erasca, Inc. files periodic reports with the SEC as ERAS on Nasdaq. Atlas tracks 20 filed reports for this issuer, each linked to its original EDGAR accession.

Next window
24 Jul 2026 – 31 Aug 2026
Latest report
10-Q
Period ended
31 Mar 2026
Filed
11 May 2026
Reports on record
20

How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 43 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.

Open ERAS market profile Latest filing on SEC EDGAR ↗ Pharmaceutical Preparations reporting datesAll Nasdaq reporting dates

Filed periodic reports

FormPeriod endedFiledLagSEC accession
10-Q31 Mar 202611 May 202641 days0001193125-26-216788
10-K31 Dec 202512 Mar 202671 days0001193125-26-104150
10-Q30 Sep 202512 Nov 202543 days0001193125-25-277625
10-Q30 Jun 202512 Aug 202543 days0001193125-25-178996
10-Q31 Mar 202513 May 202543 days0000950170-25-070418
10-K31 Dec 202420 Mar 202579 days0000950170-25-042682
10-Q30 Sep 202412 Nov 202443 days0000950170-24-125481
10-Q30 Jun 202412 Aug 202443 days0000950170-24-095437
10-Q31 Mar 20248 May 202438 days0000950170-24-055668
10-K31 Dec 202327 Mar 202487 days0000950170-24-037193
10-Q30 Sep 20239 Nov 202340 days0000950170-23-062094
10-Q30 Jun 202310 Aug 202341 days0000950170-23-041333
10-Q31 Mar 202315 May 202345 days0000950170-23-022282
10-K31 Dec 202223 Mar 202382 days0000950170-23-009496
10-Q30 Sep 20229 Nov 202240 days0000950170-22-023926
10-Q30 Jun 202211 Aug 202242 days0000950170-22-016907
10-Q31 Mar 202212 May 202242 days0000950170-22-009720
10-K31 Dec 202124 Mar 202283 days0000950170-22-004557
10-Q30 Sep 202110 Nov 202141 days0000950170-21-004131
10-Q30 Jun 202126 Aug 202157 days0000950170-21-001573

Source: SEC EDGAR company submissions for CIK 0001761918. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.